Liquidia to Present at Upcoming Investor Conferences
Rhea-AI Summary
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, from 11:00 to 11:35 a.m. ET, and at the 2024 Cantor Global Healthcare Conference in New York on September 19, from 1:30 to 1:50 p.m. ET.
Investors and interested parties can access the webcasts of these presentations through Liquidia's website. Recorded versions of the presentations will be available on the company's website for at least 30 days following each event, providing an opportunity for those unable to attend live to review the information presented.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LQDA declined 1.14%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MORRISVILLE, N.C., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the following investor conferences this September:
- 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, from 11:00 – 11:35 a.m. ET
- 2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, from 1:30 – 1:50 p.m. ET
Access to the webcasts will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of each presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com
FAQ
When and where is Liquidia (LQDA) presenting at investor conferences in September 2024?
How can investors access Liquidia's (LQDA) presentations at the September 2024 conferences?
How long will Liquidia's (LQDA) September 2024 conference presentations be available online?
What is the focus of Liquidia (LQDA)?
